NLRP3 and heart failure: Oral NR (2000 mg daily) administration for 5–9 days in four patients with stage D heart failure resulted in an increase of whole blood NAD+ levels, a consistent enhancement of basal and maximal respiration in peripheral blood mononuclear cells, and an up to 30-fold reduction of NLRP3 and inflammatory cytokines.